MCRB

Seres Therapeutics (MCRB)

About Seres Therapeutics (MCRB)

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Details

Daily high

$0.96

Daily low

$0.92

Price at open

$0.93

52 Week High

$2.05

52 Week Low

$0.54

Market cap

156.3M

Dividend yield

0.00%

Volume

2.8M

Avg. volume

2.9M

P/E ratio

-.77

Seres Therapeutics News